Andrew M. Goldsweig, MD

The First 4 Years of Postmarketing Safety Surveillance Related to the MitraClip Device: A United States Food and Drug Administration MAUDE Experience

04/08/2020

Andrew M. Goldsweig , MD;

Muthiah Vaduganathan , MD, MPH;

Chetaj A. Mahabir , MBBS;

Sourabh Aggarwal , MD;

Anandbir Bath , MD;

Arman Qamar , MD;

Nilay K. Patel , MD;

Abstract: Objective. The MitraClip (Abbott) is a commercially available device to perform percutaneous transcatheter mitral valve repair (TMVR) for patients with symptomatic mitral regurgitation (MR). Recent data support its role in...

Abstract: Objective. The...

04/08/2020

Journal of Invasive Cardiology

Brief Communication

The Single-Access Technique for Impella Protected Percutaneous Coronary Intervention: A Single-Center Experience

03/01/2022

Poonam Velagapudi , MD, MS;

David E. Barton , MD;

Andrew M. Goldsweig , MD;

Yiannis S. Chatzizisis , MD, PhD;

Gregory Pavlides , MD;

Ganesh Gajanan , MD;

Edward O'Leary , MD, MBA;

In this era of complex high-risk percutaneous coronary intervention (HR-PCI), mechanical support is being increasingly used. Traditionally, mechanical circulatory support with the Impella CP device requires a large-bore arterial access and an...

In this era of complex high-risk...

03/01/2022

Journal of Invasive Cardiology